BMS 919373

Drug Profile

BMS 919373

Alternative Names: BMS-919373; Ikur inhibitor - Bristol-Myers Squibb

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bristol-Myers Squibb
  • Class Antiarrhythmics; Pyridines; Quinazolines; Small molecules; Sulfonamides
  • Mechanism of Action Kv1.5 potassium channel inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute coronary syndromes; Atrial fibrillation; Paroxysmal atrial fibrillation

Most Recent Events

  • 07 Mar 2017 Chemical structure information added
  • 14 Feb 2017 Bristol-Myers Squibb terminates a phase I trial in Atrial fibrillation in USA and Canada due to insufficient enrolment(NCT02153437)
  • 01 Jan 2017 Discontinued - Phase-I for Acute coronary syndromes (In volunteers) in USA (PO, Suspension)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top